JP2013545812A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013545812A5 JP2013545812A5 JP2013544762A JP2013544762A JP2013545812A5 JP 2013545812 A5 JP2013545812 A5 JP 2013545812A5 JP 2013544762 A JP2013544762 A JP 2013544762A JP 2013544762 A JP2013544762 A JP 2013544762A JP 2013545812 A5 JP2013545812 A5 JP 2013545812A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- crystalline form
- pyrimidine
- sulfonyl
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 21
- -1 2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl Chemical group 0.000 claims description 20
- 239000013078 crystal Substances 0.000 claims description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 13
- 239000012535 impurity Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims description 4
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 238000000354 decomposition reaction Methods 0.000 claims description 4
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 238000002844 melting Methods 0.000 claims description 4
- 230000008018 melting Effects 0.000 claims description 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 238000002411 thermogravimetry Methods 0.000 claims description 4
- 230000004580 weight loss Effects 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 3
- 239000000376 reactant Substances 0.000 claims description 3
- LWJRPYKKVVWJPM-UHFFFAOYSA-N 4-n-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine Chemical compound CC(C)S(=O)(=O)C1=CC=CC=C1NC1=CC=NC(N)=N1 LWJRPYKKVVWJPM-UHFFFAOYSA-N 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000012609 Cowden disease Diseases 0.000 claims description 2
- 201000002847 Cowden syndrome Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000007727 Muscle Tissue Neoplasms Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 210000001015 abdomen Anatomy 0.000 claims description 2
- 210000004100 adrenal gland Anatomy 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000000621 bronchi Anatomy 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000002758 colorectal adenoma Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 210000004696 endometrium Anatomy 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 210000003494 hepatocyte Anatomy 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 210000003228 intrahepatic bile duct Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000000244 kidney pelvis Anatomy 0.000 claims description 2
- 210000000867 larynx Anatomy 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 2
- 210000000214 mouth Anatomy 0.000 claims description 2
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- 208000024305 myofibroblastoma Diseases 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 210000003800 pharynx Anatomy 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- 201000010700 sporadic breast cancer Diseases 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 210000001215 vagina Anatomy 0.000 claims description 2
- RGUSBQMVNZUQBV-UHFFFAOYSA-N 5-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine Chemical compound CC(C)S(=O)(=O)C1=CC=CC=C1C1=CN=C(N)N=C1N RGUSBQMVNZUQBV-UHFFFAOYSA-N 0.000 claims 1
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 claims 1
- 150000004985 diamines Chemical class 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- FJNLCHNQVJVCPY-UHFFFAOYSA-N 2-n-methoxy-2-n-methyl-4-n,6-n-dipropyl-1,3,5-triazine-2,4,6-triamine Chemical compound CCCNC1=NC(NCCC)=NC(N(C)OC)=N1 FJNLCHNQVJVCPY-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061424194P | 2010-12-17 | 2010-12-17 | |
| US61/424,194 | 2010-12-17 | ||
| PCT/US2011/065030 WO2012082972A1 (en) | 2010-12-17 | 2011-12-15 | Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013545812A JP2013545812A (ja) | 2013-12-26 |
| JP2013545812A5 true JP2013545812A5 (enExample) | 2015-01-15 |
| JP5916752B2 JP5916752B2 (ja) | 2016-05-11 |
Family
ID=45464892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013544762A Active JP5916752B2 (ja) | 2010-12-17 | 2011-12-15 | ５−クロロ−ｎ２−（２−イソプロポキシ−５−メチル−４−ピペリジン−４−イル−フェニル）−ｎ４［２−（プロパン−２−スルホニル）−フェニル］−ピリミジン−２，４−ジアミンの結晶形 |
Country Status (36)
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013015000A2 (pt) * | 2010-12-17 | 2016-08-09 | Novartis Ag | formas cristalinas de 5-cloron2-(2-isopropóxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propano-2-sulfonil)-fenil]-pirimidina-2,4-diamina |
| CN104854101B (zh) | 2012-11-06 | 2018-05-01 | 上海复尚慧创医药研究有限公司 | Alk激酶抑制剂 |
| KR101656382B1 (ko) * | 2014-02-28 | 2016-09-09 | 한국화학연구원 | 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
| CN105272921A (zh) * | 2014-06-09 | 2016-01-27 | 江苏奥赛康药业股份有限公司 | 一种制备Ceritinib的方法及其中间体化合物 |
| CN105294649B (zh) * | 2014-07-30 | 2019-05-14 | 江苏奥赛康药业股份有限公司 | 一种Ceritinib化合物及其药物组合物 |
| CN105294650A (zh) * | 2014-08-01 | 2016-02-03 | 江苏奥赛康药业股份有限公司 | 一种Ceritinib化合物及其药物组合物 |
| UA119794C2 (uk) | 2014-10-21 | 2019-08-12 | Аріад Фармасьютикалз, Інк. | Кристалічна форма 5-хлор-n4-[2-(диметилфосфорил)феніл]-n2-{2-метокси-4-[4-(4-метилпіперазин-1-іл)піперидин-1-іл]}піримідин-2,4-діаміну |
| WO2016081538A1 (en) | 2014-11-18 | 2016-05-26 | Teva Pharmaceuticals International Gmbh | Solid state forms of ceritinib and salts thereof |
| CN105601614A (zh) * | 2014-11-21 | 2016-05-25 | 奥浦顿（上海）医药科技有限公司 | 一种色瑞替尼晶型及其制备方法 |
| WO2016082795A1 (zh) * | 2014-11-28 | 2016-06-02 | 苏州晶云药物科技有限公司 | 色瑞替尼的晶型i及其制备方法 |
| CN105622577A (zh) * | 2014-11-29 | 2016-06-01 | 江苏先声药业有限公司 | 一种色瑞替尼的新晶型及其制备方法 |
| WO2016108123A2 (en) * | 2014-12-17 | 2016-07-07 | Dr. Reddy’S Laboratories Limited | Pure amorphous and amorphous solid dispersion of ceritinib |
| WO2016098070A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine |
| WO2016098042A1 (en) * | 2014-12-19 | 2016-06-23 | Novartis Ag | Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders |
| WO2017016529A1 (en) | 2015-07-28 | 2017-02-02 | Zentiva, K.S. | Solid forms of ceritinib free base |
| CN105061397B (zh) * | 2015-08-07 | 2018-01-02 | 武汉英普瑞医药科技有限公司 | 一种色瑞替尼的c型晶型及其制备方法与应用 |
| CN106699743B (zh) | 2015-11-05 | 2020-06-12 | 湖北生物医药产业技术研究院有限公司 | 嘧啶类衍生物及其用途 |
| WO2017152858A1 (zh) * | 2016-03-11 | 2017-09-14 | 苏州晶云药物科技有限公司 | 色瑞替尼的晶型及其制备方法 |
| WO2017158619A1 (en) | 2016-03-15 | 2017-09-21 | Natco Pharma Limited | A modified process for the preparation of ceritinib and amorphous form of ceritinib |
| JP2019196359A (ja) * | 2019-06-17 | 2019-11-14 | ノバルティス アーゲー | ピリミジン誘導体およびそれらの中間体を調製する化学的方法 |
| GB201915618D0 (en) | 2019-10-28 | 2019-12-11 | Univ Oslo | ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases |
| CN113135905B (zh) | 2020-01-17 | 2023-11-21 | 轩竹生物科技股份有限公司 | 多环类间变性淋巴瘤激酶抑制剂的晶型 |
| US12583835B2 (en) * | 2020-03-30 | 2026-03-24 | Jiangsu Yahong Meditech Co., Ltd. | Crystal form of nitroxoline prodrug, pharmaceutical composition containing same, and preparation method therefor and application thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| PT1660458E (pt) * | 2003-08-15 | 2012-04-27 | Novartis Ag | 2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário |
| GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| NZ577197A (en) | 2006-12-08 | 2011-02-25 | Irm Llc | Pyrimidine compounds especially 4-phenylamino-2-arylamino-pyrimidine derivatives and compositions as protein kinase inhibitors |
| EA017405B9 (ru) | 2006-12-08 | 2014-05-30 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве ингибиторов протеинкиназы |
| EA017252B1 (ru) * | 2007-08-28 | 2012-11-30 | Айрм Ллк | Производные 2-бифениламино-4-аминопиримидина в качестве ингибиторов киназ |
| AU2008296479A1 (en) * | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
| MX2010010968A (es) * | 2008-04-07 | 2010-10-26 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa de proteina. |
| MX353308B (es) * | 2008-05-21 | 2018-01-08 | Ariad Pharma Inc | Derivados fosforosos como inhibidores de cinasa. |
| CA2763717A1 (en) * | 2009-06-10 | 2010-12-16 | Cellzome Limited | Pyrimidine derivatives as zap-70 inhibitors |
| TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| CN103596929B (zh) | 2010-12-17 | 2016-10-19 | 里亚塔医药公司 | 作为抗氧化发炎调节剂的吡唑及嘧啶三环烯酮 |
| BR112013015000A2 (pt) * | 2010-12-17 | 2016-08-09 | Novartis Ag | formas cristalinas de 5-cloron2-(2-isopropóxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propano-2-sulfonil)-fenil]-pirimidina-2,4-diamina |
| WO2012082580A2 (en) | 2010-12-17 | 2012-06-21 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
| CN105294650A (zh) | 2014-08-01 | 2016-02-03 | 江苏奥赛康药业股份有限公司 | 一种Ceritinib化合物及其药物组合物 |
| WO2016081538A1 (en) | 2014-11-18 | 2016-05-26 | Teva Pharmaceuticals International Gmbh | Solid state forms of ceritinib and salts thereof |
| DE112015005255B4 (de) | 2014-11-21 | 2023-10-26 | Joyson Safety Systems Acquisition Llc | Airbagmodul |
| CN105622577A (zh) | 2014-11-29 | 2016-06-01 | 江苏先声药业有限公司 | 一种色瑞替尼的新晶型及其制备方法 |
| EP3227335A1 (en) | 2014-12-04 | 2017-10-11 | Bristol-Myers Squibb Company | Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma) |
| WO2016098070A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine |
| WO2017016529A1 (en) | 2015-07-28 | 2017-02-02 | Zentiva, K.S. | Solid forms of ceritinib free base |
| CN105061397B (zh) | 2015-08-07 | 2018-01-02 | 武汉英普瑞医药科技有限公司 | 一种色瑞替尼的c型晶型及其制备方法与应用 |
-
2011
- 2011-12-15 BR BR112013015000A patent/BR112013015000A2/pt not_active Application Discontinuation
- 2011-12-15 MX MX2013006952A patent/MX338210B/es active IP Right Grant
- 2011-12-15 HR HRP20171477TT patent/HRP20171477T1/hr unknown
- 2011-12-15 RS RS20181240A patent/RS57771B1/sr unknown
- 2011-12-15 LT LTEP11806079.7T patent/LT2651918T/lt unknown
- 2011-12-15 SI SI201131289T patent/SI2651918T1/sl unknown
- 2011-12-15 CN CN202011050061.0A patent/CN112125884A/zh active Pending
- 2011-12-15 SG SG10201510082XA patent/SG10201510082XA/en unknown
- 2011-12-15 US US13/993,217 patent/US9309229B2/en active Active
- 2011-12-15 CN CN201610217386.0A patent/CN106008462A/zh active Pending
- 2011-12-15 KR KR1020137018605A patent/KR20130130022A/ko not_active Withdrawn
- 2011-12-15 CN CN201710063793.5A patent/CN107056751A/zh active Pending
- 2011-12-15 EP EP18186197.2A patent/EP3453708B8/en active Active
- 2011-12-15 KR KR1020197005138A patent/KR20190022903A/ko not_active Ceased
- 2011-12-15 LT LTEP16167355.3T patent/LT3121171T/lt unknown
- 2011-12-15 DK DK11806079.7T patent/DK2651918T3/en active
- 2011-12-15 PL PL11806079T patent/PL2651918T3/pl unknown
- 2011-12-15 EP EP11806079.7A patent/EP2651918B1/en not_active Revoked
- 2011-12-15 PT PT118060797T patent/PT2651918T/pt unknown
- 2011-12-15 ES ES16167355T patent/ES2696526T3/es active Active
- 2011-12-15 MY MYPI2016001551A patent/MY177742A/en unknown
- 2011-12-15 PE PE2013001425A patent/PE20140698A1/es not_active Application Discontinuation
- 2011-12-15 CN CN201180060435XA patent/CN103282359A/zh active Pending
- 2011-12-15 RU RU2013132947A patent/RU2599785C3/ru active Protection Beyond IP Right Term
- 2011-12-15 ES ES11806079.7T patent/ES2643016T3/es active Active
- 2011-12-15 DK DK16167355.3T patent/DK3121171T3/en active
- 2011-12-15 PL PL16167355T patent/PL3121171T3/pl unknown
- 2011-12-15 WO PCT/US2011/065030 patent/WO2012082972A1/en not_active Ceased
- 2011-12-15 CA CA2821102A patent/CA2821102C/en active Active
- 2011-12-15 SI SI201131583T patent/SI3121171T1/sl unknown
- 2011-12-15 EP EP16167355.3A patent/EP3121171B1/en active Active
- 2011-12-15 ES ES18186197T patent/ES2905973T3/es active Active
- 2011-12-15 JP JP2013544762A patent/JP5916752B2/ja active Active
- 2011-12-15 RU RU2016136823A patent/RU2746159C2/ru active
- 2011-12-15 CN CN201410457562.9A patent/CN104262324A/zh active Pending
- 2011-12-15 KR KR1020187007996A patent/KR20180032680A/ko not_active Ceased
- 2011-12-15 PT PT16167355T patent/PT3121171T/pt unknown
- 2011-12-15 AU AU2011343775A patent/AU2011343775B2/en active Active
- 2011-12-15 CN CN202210792464.5A patent/CN114989139A/zh active Pending
- 2011-12-15 KR KR1020207009828A patent/KR102325775B1/ko active Active
- 2011-12-15 HU HUE16167355A patent/HUE041845T2/hu unknown
- 2011-12-15 AR ARP110104703A patent/AR084309A1/es not_active Application Discontinuation
- 2011-12-15 PH PH1/2013/501254A patent/PH12013501254A1/en unknown
- 2011-12-15 NZ NZ610713A patent/NZ610713A/en not_active IP Right Cessation
- 2011-12-15 MY MYPI2013001848A patent/MY164810A/en unknown
- 2011-12-15 CN CN201710063792.0A patent/CN106831716A/zh active Pending
- 2011-12-15 SG SG2013039342A patent/SG190856A1/en unknown
- 2011-12-16 TW TW105112710A patent/TWI576344B/zh active
- 2011-12-16 TW TW100146987A patent/TWI576343B/zh active
-
2013
- 2013-05-17 ZA ZA2013/03599A patent/ZA201303599B/en unknown
- 2013-05-17 TN TNP2013000216A patent/TN2013000216A1/fr unknown
- 2013-05-20 IL IL226474A patent/IL226474A/en active IP Right Grant
- 2013-06-14 CL CL2013001723A patent/CL2013001723A1/es unknown
- 2013-06-17 GT GT201300153A patent/GT201300153A/es unknown
- 2013-06-28 MA MA36066A patent/MA34771B1/fr unknown
- 2013-07-04 CO CO13158446A patent/CO6801792A2/es not_active Application Discontinuation
- 2013-07-16 EC ECSP13012770 patent/ECSP13012770A/es unknown
-
2016
- 2016-03-02 US US15/058,489 patent/US20160175305A1/en not_active Abandoned
-
2017
- 2017-10-11 CY CY20171101064T patent/CY1119474T1/el unknown
-
2018
- 2018-10-22 HR HRP20181737TT patent/HRP20181737T1/hr unknown
- 2018-11-09 CY CY181101192T patent/CY1121017T1/el unknown
-
2021
- 2021-03-19 AR ARP210100698A patent/AR122395A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013545812A5 (enExample) | ||
| RU2013132947A (ru) | Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина | |
| JP6206689B2 (ja) | ５−アミノ−２，３−ジヒドロフタラジン−１，４−ジオンナトリウム塩の結晶形ｉまたはｉｉを含有する医薬製剤 | |
| JP2021530565A5 (enExample) | ||
| JP2020511467A5 (enExample) | ||
| JP2017535550A5 (enExample) | ||
| CN108143745A (zh) | 包含六氧化四砷的多晶型物的用于预防或治疗肝癌的药物组合物 | |
| CN116672363A (zh) | 六氧化四砷组合物在制备用于预防或治疗癌的药物组合物中的用途 | |
| JP2018536705A5 (enExample) | ||
| WO2021017880A1 (zh) | 一类靶向stat3双功能磷酸化位点的三芳香环类化合物及其应用 | |
| WO2009114994A1 (zh) | 哒嗪酮类化合物在制备抗肿瘤药物中的用途 | |
| JP2014524476A5 (enExample) | ||
| JP2019516749A5 (enExample) | ||
| JP2017526662A5 (enExample) | ||
| JP2018509380A5 (enExample) | ||
| JP2020521732A5 (enExample) | ||
| JP2016537326A5 (enExample) | ||
| RU2014104993A (ru) | Кристаллическая форма натриевой соли 4-трет-бутил-n-{4-хлор-2-(1-окси-пиридин-4-карбонил)-фенил}-бензолсульфонамид | |
| JP2017535510A (ja) | マルトール第二鉄の結晶形態 | |
| RU2012136921A (ru) | Твердые формы, содержащие производные циклопропиламида | |
| TWI374880B (en) | A pharmaceutically acceptable salt and solvate of n-[3-[[[2-[(2,3-dihydro-2-oxo-1h-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-2-pyridinyl]-n-methylmethanesulfonamide and uses thereof | |
| KR20150054860A (ko) | 포스파티딜이노시톨 3-키나아제 억제제의 정제 제형 | |
| CN105753869B (zh) | 一种cdk抑制剂和mek抑制剂的共晶及其制备方法 | |
| JP2018500355A5 (enExample) | ||
| CA3020239C (en) | Processes for preparing oxathiazin-like compounds |